vs
Side-by-side financial comparison of Celularity Inc (CELU) and Falcon's Beyond Global, Inc. (FBYD). Click either name above to swap in a different company.
Falcon's Beyond Global, Inc. is the larger business by last-quarter revenue ($6.6M vs $5.3M, roughly 1.2× Celularity Inc). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -436.7%, a 432.2% gap on every dollar of revenue. On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs -43.2%). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs -33.9%).
Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.
500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.
CELU vs FBYD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $6.6M |
| Net Profit | $-23.1M | $-296.0K |
| Gross Margin | 26.1% | — |
| Operating Margin | -244.1% | -30.9% |
| Net Margin | -436.7% | -4.5% |
| Revenue YoY | -43.2% | 383.5% |
| Net Profit YoY | -43.3% | 97.5% |
| EPS (diluted) | $-0.88 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.6M | ||
| Q3 25 | $5.3M | $4.1M | ||
| Q2 25 | $5.7M | $2.5M | ||
| Q1 25 | $11.4M | $1.7M | ||
| Q4 24 | $18.1M | $1.4M | ||
| Q3 24 | $9.3M | $2.1M | ||
| Q2 24 | $12.1M | $1.8M | ||
| Q1 24 | $14.7M | $1.5M |
| Q4 25 | — | $-296.0K | ||
| Q3 25 | $-23.1M | $-10.4M | ||
| Q2 25 | $-24.5M | $25.1M | ||
| Q1 25 | $-19.8M | $-8.1M | ||
| Q4 24 | $-13.3M | $-11.9M | ||
| Q3 24 | $-16.1M | $39.3M | ||
| Q2 24 | $-6.5M | $8.0M | ||
| Q1 24 | $-22.0M | $114.0M |
| Q4 25 | — | — | ||
| Q3 25 | 26.1% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | 68.9% | — | ||
| Q4 24 | 59.5% | — | ||
| Q3 24 | 58.2% | — | ||
| Q2 24 | 82.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | — | -30.9% | ||
| Q3 25 | -244.1% | -90.9% | ||
| Q2 25 | -276.6% | -53.0% | ||
| Q1 25 | -91.8% | -371.1% | ||
| Q4 24 | -51.2% | -335.6% | ||
| Q3 24 | -124.0% | -118.9% | ||
| Q2 24 | -84.0% | -195.9% | ||
| Q1 24 | -50.2% | -350.5% |
| Q4 25 | — | -4.5% | ||
| Q3 25 | -436.7% | -256.8% | ||
| Q2 25 | -427.5% | 985.2% | ||
| Q1 25 | -172.9% | -473.8% | ||
| Q4 24 | -73.3% | -871.7% | ||
| Q3 24 | -173.2% | 1899.5% | ||
| Q2 24 | -53.6% | 446.5% | ||
| Q1 24 | -149.9% | 7521.4% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | $-0.88 | $-0.13 | ||
| Q2 25 | $-1.02 | $0.30 | ||
| Q1 25 | $-0.84 | $-0.13 | ||
| Q4 24 | $-0.58 | $-0.25 | ||
| Q3 24 | $-0.73 | $0.39 | ||
| Q2 24 | $-0.30 | $0.00 | ||
| Q1 24 | $-1.03 | $1.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0K | $1.9M |
| Total DebtLower is stronger | $35.7M | $15.6M |
| Stockholders' EquityBook value | $-20.1M | $11.9M |
| Total Assets | $114.2M | $66.7M |
| Debt / EquityLower = less leverage | — | 1.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.9M | ||
| Q3 25 | $120.0K | $4.3M | ||
| Q2 25 | $863.0K | $26.1M | ||
| Q1 25 | $293.0K | $1.1M | ||
| Q4 24 | $738.0K | $825.0K | ||
| Q3 24 | $133.0K | $828.0K | ||
| Q2 24 | $467.0K | $1.7M | ||
| Q1 24 | $1.9M | $1.1M |
| Q4 25 | — | $15.6M | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | $10.3M | ||
| Q2 24 | — | $15.7M | ||
| Q1 24 | — | $15.1M |
| Q4 25 | — | $11.9M | ||
| Q3 25 | $-20.1M | $9.2M | ||
| Q2 25 | $-25.5M | $414.0K | ||
| Q1 25 | $-5.5M | $-11.6M | ||
| Q4 24 | $8.8M | $-9.0M | ||
| Q3 24 | $17.3M | $-1.4M | ||
| Q2 24 | $27.8M | $-44.7M | ||
| Q1 24 | $31.2M | $-61.7M |
| Q4 25 | — | $66.7M | ||
| Q3 25 | $114.2M | $66.8M | ||
| Q2 25 | $120.3M | $89.2M | ||
| Q1 25 | $128.9M | $56.7M | ||
| Q4 24 | $132.7M | $61.2M | ||
| Q3 24 | $128.8M | $66.5M | ||
| Q2 24 | $135.5M | $65.9M | ||
| Q1 24 | $143.8M | $67.8M |
| Q4 25 | — | 1.31× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $-4.3M |
| Free Cash FlowOCF − Capex | — | $-4.3M |
| FCF MarginFCF / Revenue | — | -66.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $-4.2M | $-13.3M | ||
| Q2 25 | $-999.0K | $-7.9M | ||
| Q1 25 | $-3.0M | $945.0K | ||
| Q4 24 | $1.6M | $-3.8M | ||
| Q3 24 | $-144.0K | $-2.4M | ||
| Q2 24 | $-3.4M | $-2.6M | ||
| Q1 24 | $-4.4M | $-3.8M |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $-13.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $853.0K | ||
| Q4 24 | $1.5M | $-3.8M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-3.5M | $-2.6M | ||
| Q1 24 | $-4.4M | $-3.8M |
| Q4 25 | — | -66.0% | ||
| Q3 25 | — | -329.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | 8.3% | -278.7% | ||
| Q3 24 | — | -114.9% | ||
| Q2 24 | -28.7% | -145.6% | ||
| Q1 24 | -30.3% | -248.8% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.3% | 0.1% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.06× | ||
| Q2 24 | — | -0.33× | ||
| Q1 24 | — | -0.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
FBYD
Segment breakdown not available.
